Bolt Biotherapeutics (BOLT) AI Stock Analysis

• Market Cap: $16.29M
• Dividend Yield: N/A
• Average Volume (3M): 114.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: -2.36%
• EPS Growth: 9.68%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 38,339,700
• 10 Day Avg. Volume: 162,897
• 30 Day Avg. Volume: 114,008
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.72
• Price to Cash Flow (P/CF): -0.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.13
• Price Target Upside: 169.05% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

Bolt Biotherapeutics faces significant challenges with ongoing financial losses and cash flow inefficiencies. Although the balance sheet shows a stable equity position and low debt, the lack of profitability and negative valuation metrics significantly impact the stock's attractiveness. Technical analysis shows a bearish trend, adding further pressure on the stock's outlook.

Positive Factors

Clinical Data

Initial Ph 1 dose-escalation data for BDC-3042 at AACR is expected to reveal encouraging clinical signals, including a favorable safety profile and evidence of pharmacodynamic engagement.

Clinical Development

Bolt Biotherapeutics has made encouraging progress on their two lead assets, BDC-3042 and BDC-4182.

Negative Factors

Clinical Trials

The stock is expected to remain pressured until clinical trials play out in 2025.

Financial Performance

Bolt reported 4Q24 revenue of $0.0M and EPS of ($0.42), compared to estimates of $0.9M and ($0.34), respectively.

Bolt Biotherapeutics Business Overview & Revenue Model

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

How the Company Makes Money

Bolt Biotherapeutics makes money primarily through the development and commercialization of its proprietary cancer therapies. The company's revenue model includes potential milestone payments and royalties from licensing agreements and partnerships with larger pharmaceutical companies. These collaborations help in the advancement of its drug candidates through clinical trials and regulatory approval processes. Additionally, Bolt may secure funding through equity offerings, grants, or government contracts to support its research and development activities. The company's earnings are influenced by the successful progression and commercialization of its drug pipeline.

Bolt Biotherapeutics Financial Statement Overview

Summary

Bolt Biotherapeutics faces significant financial challenges with persistent unprofitability and negative cash flows. While there is some revenue growth, it is insufficient to achieve profitability. The balance sheet shows improvement in equity stability, but the company remains in a precarious financial position due to ongoing losses and cash usage. Strategic shifts may be required to achieve sustainable financial health.

Income Statement

Bolt Biotherapeutics exhibits a challenging income statement profile with negative margins across the board. The Gross Profit Margin is negative due to high costs, and the Net Profit Margin remains deeply negative despite some revenue growth from 2022 to 2023. EBIT and EBITDA margins are also negative, indicating ongoing operational challenges. While there is some revenue growth, the overall profitability remains under pressure.

Balance Sheet

The balance sheet reflects a moderately leveraged position with a Debt-to-Equity Ratio that has improved from negative equity in 2020. Stockholders' equity has been positive since 2021, providing some stability. However, the Return on Equity (ROE) remains negative, indicating continued unprofitability. The Equity Ratio reflects a healthy proportion of equity relative to total assets, which is a positive aspect of the balance sheet.

Cash Flow

Cash flow analysis shows continuous negative free cash flow, although there is an improvement in the Free Cash Flow Growth Rate from 2023 to the TTM period. The Operating Cash Flow to Net Income ratio is negative, reflecting the ongoing cash burn. Despite capital inflows, the company struggles with cash flow from operations, which poses a risk to liquidity.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
9.78M	7.88M	5.73M	1.26M	231.00K	215.00K
	Gross Profit
-6.61M	5.99M	838.00K	-2.41M	-40.13M	-25.79M
	EBIT
-75.90M	-76.20M	-90.32M	-92.79M	-49.18M	-30.97M
	EBITDA
-70.51M	-74.34M	-88.66M	-91.59M	-48.57M	-30.63M
	Net Income Common Stockholders
-65.08M	-69.20M	-85.88M	-104.39M	-72.27M	-30.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
34.83M	102.19M	168.89M	186.22M	22.84M	34.83M
	Total Assets
48.45M	159.78M	227.81M	307.72M	46.54M	48.45M
	Total Debt
10.19M	20.22M	22.61M	24.36M	10.88M	10.19M
	Net Debt
-24.64M	9.41M	13.37M	-3.03M	5.33M	-24.64M
	Total Liabilities
94.29M	47.04M	56.30M	57.60M	151.49M	94.29M
	Stockholders Equity
-45.85M	112.74M	171.51M	250.12M	-104.95M	-45.85M
Cash Flow		Free Cash Flow
-61.17M	-69.73M	-78.46M	-59.40M	-50.57M	-26.85M
	Operating Cash Flow
-61.12M	-69.53M	-76.50M	-57.07M	-47.31M	-26.34M
	Investing Cash Flow
61.15M	71.04M	57.86M	-232.20M	-20.59M	-508.00K
	Financing Cash Flow
185.00K	253.00K	503.00K	311.11M	39.60M	48.63M

Bolt Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 0.42 is below the 20-day moving average (MA) of 0.43, below the 50-day MA of 0.47, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.69 is Neutral, neither overbought nor oversold. The STOCH value of 50.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.

Bolt Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	19.94%	1.20%
IOVA	48 Neutral	$1.17B	―	-57.48%	―	13698.99%	31.46%
BOLT	46 Neutral	$16.29M	―	-74.28%	―	-2.36%	9.68%
ADAP	46 Neutral	$52.72M	―	-273.36%	―	194.23%	45.50%
IMTX	45 Neutral	$552.62M	57.44	3.73%	―	188.64%	―
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%
AFMD	42 Neutral	$11.89M	―	-151.46%	―	-95.23%	-325.89%

Bolt Biotherapeutics Corporate Events

Bolt Biotherapeutics Announces Board Changes and Appointments

Dr. Mahendra Shah resigned from Bolt Biotherapeutics’ Board of Directors, effective December 31, 2024, for personal reasons. Following his resignation, Dr. Jakob Dupont was appointed to the Audit Committee and the Nominating and Corporate Governance Committee, ensuring continuity in the company’s governance.